Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?

Selection of the right drug for the right patient is a promising approach to increase clinical benefit of targeted therapy with monoclonal antibodies (mAbs). Assessment of in vivo biodistribution and tumor targeting of mAbs to predict toxicity and efficacy is expected to guide individualized treatme...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Jauw, Yvonne W. S., Menke-van der Houven van Oordt, C. Willemien, Hoekstra, Otto S., Hendrikse, N. Harry, Vugts, Danielle J., Zijlstra, Josée M., Huisman, Marc C., van Dongen, Guus A. M. S.
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2016
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4877495/
https://ncbi.nlm.nih.gov/pubmed/27252651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00131
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados